Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system

Erik Kohlbrenner, George Aslanidi, Kevin Nash, Stanislav Shklyaev, Martha Campbell-Thompson, Barry J. Byrne, Richard O. Snyder, Nicholas Muzyczka, Kenneth H. Warrington, Sergei Zolotukhin

Research output: Contribution to journalArticlepeer-review

75 Scopus citations

Abstract

Scalable production of rAAV vectors remains a major obstacle to the clinical application of this prototypical gene therapy vector. A recently developed baculovirus-based production protocol (M. Urabe et al., 2002, Hum. Gene Ther. 13, 1935-1943) found limited applications due to the system's design. Here we report a detailed analysis of the stability of the original baculovirus system components BacRep, BacVP, and transgene cassette-containing BacGFP. All of the baculovirus helpers analyzed were prone to passage-dependent loss-of-function deletions resulting in considerable decreases in rAAV titers. To alleviate the instability and to extend the baculovirus platform to other rAAV serotypes, we have modified both Rep- and Cap-encoding components of the original system. The modifications include a parvoviral phospholipase A2 domain swap allowing production of infectious rAAV8 vectors in vivo. Alternatively, an infectious rAAV8 (or rAAV5) vector incorporating the AAV2 VP1 capsid protein in a mosaic vector particle with AAV8 capsid proteins was produced using a novel baculovirus vector. In this vector, the level of AAV2 VP1 expression is controlled with a "riboswitch," a self-cleaving ribozyme controlled by toyocamycin in the "ON" mode. The redesigned baculovirus system improves our capacity for rAAV manufacturing by making this production platform more applicable to other existing serotypes.

Original languageEnglish (US)
Pages (from-to)1217-1225
Number of pages9
JournalMolecular Therapy
Volume12
Issue number6
DOIs
StatePublished - Dec 2005
Externally publishedYes

Bibliographical note

Funding Information:
This study was supported in part by National Institutes of Health Grants NIDDK-R01 DK62302, NHLBI-P50-HL59412, P01-DK58327, and JDFI Center Grant. S.Z., N.M., B.J.B., and R.O.S. are inventors on patents related to recombinant AAV technology and own equity in a gene therapy company (AGTC) that is commercializing AAV for gene therapy applications.

Keywords

  • AAV
  • Baculovirus
  • PLA2

Fingerprint Dive into the research topics of 'Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system'. Together they form a unique fingerprint.

Cite this